XNCR
Xencor, Inc.
Related News
SEC Filings
Earnings Trend
Screening
Compare
Economic Calendar
We use cookies in accordance with European GDPR standards to improve site usability, analytics, and deliver personalized advertising.Learn moreCookie Settings
Xencor remains a Strong Buy, driven by pipeline progress in oncology and inflammatory disorders. XmAb819 demonstrated a 25% response rate and 70% disease control in heavily pre-treated ccRCC patients;
